How to appeal a Blue Cross Blue Shield of Michigan specialty biologics denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Michigan-specific note: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.

What Blue Cross Blue Shield of Michigan's policy requires for specialty biologics

Cited policy: Anthem/Elevance Clinical UM Guideline clinical guideline - Adalimumab and Biosimilars

Moderate-severe disease + conventional therapy failure + TB/Hep B/C screening. Most BCBS plans now require biosimilar adalimumab first (2024-2026 adoption wave).

How Blue Cross Blue Shield of Michigan denies specialty biologics — and how to counter it

Where Blue Cross Blue Shield of Michigan pushes back: 1) Drug non-formulary; 2) Step therapy: failure of two preferred TNFi biosimilars required; 3) Lab work older than 12 months; 4) Missing rheumatologist/dermatologist/gastroenterologist attestation.

Counter-arguments that hold up: Identify the specific BCBS subsidiary and cite its named policy by number — generic appeals are weaker. For BCBS FEP: governed by FEHB; appeals to OPM after internal exhaustion (5 CFR 890.105). State external review under NAIC Model Act timelines. For self-funded ERISA BCBS plans: demand full claim file under 29 CFR 2560.503-1(h)(2)(iii).

What Blue Cross Blue Shield of Michigan typically denies for specialty biologics

Across Blue Cross Blue Shield of Michigan's commercial and Medicare books, denials cluster around a small number of patterns. For specialty biologics, expect:

• Step therapy via OptumRx (PBM since 2024)
• Site-of-care reductions for infusions
• Behavioral health prior auth
• OON balance bill disputes

Treatments most often denied in this category

These are the specialty biologics treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Stelara
• Skyrizi
• Cosentyx

How to submit the appeal to Blue Cross Blue Shield of Michigan

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Michigan cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Michigan's portal (members: https://www.bcbsm.com ; providers: https://providers.bcbsm.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MI, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Michigan's prior-authorization criteria by drug: Blue Cross Blue Shield of Michigan PA criteria on ApprovalHelp.